肝脏 ›› 2026, Vol. 31 ›› Issue (5): 729-731.

• 药物性肝损伤 • 上一篇    下一篇

美罗培南所致药物性肝损伤的临床资料和影像学表现

李益明, 刘丽萍, 罗强, 苏贝   

  1. 230000 合肥 安徽中科庚玖医院药学部
  • 收稿日期:2025-07-18 发布日期:2026-07-10
  • 通讯作者: 刘丽萍,Email:ayfyllp@126.com
  • 基金资助:
    合肥市卫生健康应用医学研究重点项目(Hwk2021zd004)

Clinical and imaging manifestations of drug-induced liver injury caused by meropenem

LI Yi-ming, LIU Li-ping, LUO Qiang, SU Bei   

  1. Department of Pharmacy, Anhui Zhongke Gengjiu Hospital , Hefei 230000, China
  • Received:2025-07-18 Published:2026-07-10
  • Contact: LIU Li-ping, Email:ayfyllp@126.com

摘要: 目的 分析美罗培南所致药物性肝损伤(DILI)患者的临床资料与影像学表现。方法 纳入2022年1月至2025年6月于安徽中科庚玖医院接受美罗培南治疗期间确诊为DILI的患者62例,其中肝细胞损伤型32例,胆汁淤积型19例和混合型11例。分析比较各分型肝功能指标及影像学表现。结果 胆汁淤积型患者ALT、AST为(55.2±17.2)U/L、(61.4±20.1)U/L,显著低于肝细胞损伤型患者的(145.3±27.8)U/L、(162.7±36.1)U/L和混合型的(137.6±38.0)U/L、(144.1±41.3)U/L(P<0.05)。肝细胞损伤型患者ALP、TBil为(96.5±25.1)U/L、(25.1±7.3)μmol/L,明显低于胆汁淤积型的(246.2±52.6)U/L、(56.2±14.7)μmol/L和混合型的(228.1±47.1)U/L、(49.5±16.1)μmol/L(P<0.05)。影像学结果显示,17例(27.4%)肝脏边缘轻度不规则或回声不均,提示可能存在肝实质炎性改变;19例(30.6%)出现肝内胆管轻度扩张,提示胆汁排泄障碍;另有22例(35.5%)伴有轻至中度脾大,可能与门静脉压力升高或系统炎症反应有关;10例(16.1%)可见胆囊壁轻度增厚。不同类型DILI患者在影像学表现方面,差异无统计学意义(P>0.05),但在胆汁淤积型及混合型中,胆管扩张及胆囊壁增厚更为常见。结论 美罗培南所致DILI表现形式复杂,既可导致以肝细胞损伤为主的急性肝炎型病变,也可引发明显的胆汁淤积及混合型损伤,不同类型DILI患者在影像学表现上无显著差异,但在胆汁淤积型及混合型中,胆管扩张及胆囊壁增厚更为常见。

关键词: 药物性肝损伤, 美罗培南, 影像学表现

Abstract: Objective To analyze the clinical data and imaging manifestations of patients with meropenem-induced drug-induced liver injury (DILI), and to provide a basis for clinical recognition, diagnosis, and treatment. Methods Sixty-two patients with DILI diagnosed during meropenem treatment in Anhui Zhongke Gengjiu Hospital between January 2022 and June 2025 were retrospectively included, which were divided into three types: hepatocellular injury type (n=32), cholestatic type (n=19) and mixed type (n=11). The liver function indexes and imaging manifestations of each type were analyzed and compared. Results The ALT and AST levels in the cholestatic type were (55.2±17.2) U/L and (61.4±20.1) U/L, respectively, which were significantly lower than those in the other two types [(145.3±27.8) U/L and (162.7±36.1) U/L; (137.6±38.0) U/L and (144.1±41.3) U/L; P<0.05]. Meanwhile, the ALP and TBil levels in the hepatocellular injury type were (96.5±25.1) U/L and (25.1±7.3) μmol/L, respectively, which were significantly lower than those in the other two types [(246.2±52.6) U/L and (56.2±14.7) μmol/L; (228.1±47.1) U/L and (49.5±16.1) μmol/L; P<0.05]. All patients underwent liver ultrasound or MRI examination. Imaging results showed that 17 patients (27.4%) had mildly irregular liver margins or heterogeneous parenchymal echotexture, suggesting possible hepatic parenchymal inflammation; 19 patients (30.6%) had mild intrahepatic bile duct dilation, indicating impaired bile excretion; 22 patients (35.5%) presented with mild to moderate splenomegaly, which might be associated with elevated portal pressure or systemic inflammatory responses; and 10 patients (16.1%) exhibited mild thickening of the gallbladder wall. There were no statistically significant differences in imaging features among different DILI types (P>0.05), although bile duct dilation and gallbladder wall thickening were more frequently observed in patients with cholestatic or mixed injury types. Conclusion Meropenem-induced DILI presents with diverse clinical manifestations, ranging from acute hepatitis characterized by hepatocellular injury to marked cholestatic or mixed-type liver injury. While no significant differences in imaging features were observed among different DILI types, bile duct dilation and gallbladder wall thickening were more commonly seen in the cholestatic and mixed types.

Key words: Drug-induced liver injury, Meropenem, Imaging manifestations